前沿生物-U
(688221)
| 流通市值：45.14亿 | | | 总市值：45.14亿 |
| 流通股本：3.75亿 | | | 总股本：3.75亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 221,972,966.63 | 248,982,710.82 | 73,999,086.35 | 374,806,392.46 |
| 应收票据及应收账款 | 38,143,925.97 | 34,750,381.75 | 43,617,532.84 | 41,221,062.46 |
| 应收账款 | 38,143,925.97 | 34,750,381.75 | 43,617,532.84 | 41,221,062.46 |
| 预付款项 | 13,631,456.2 | 11,371,343.74 | 33,648,101.66 | 30,173,139.4 |
| 其他应收款合计 | 230,454,139.14 | 227,698,043.26 | 5,896,063.02 | 5,794,203.66 |
| 其中:应收利息 | 4,008,483.42 | 1,580,575.37 | - | - |
| 存货 | 45,395,961.38 | 41,060,199.74 | 58,832,237.19 | 63,283,390.16 |
| 其他流动资产 | 56,345,260.47 | 58,224,224.75 | 214,984,015.5 | 64,404,254.55 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 1,130,068,171.69 | 1,222,617,812.37 | 1,019,445,815.4 | 1,063,499,271.46 |
| 非流动资产: | | | | |
| 长期股权投资 | 27,698,202.88 | 29,956,793.75 | - | - |
| 固定资产 | 240,692,776.45 | 245,000,007.14 | 257,484,332.71 | 261,119,704.31 |
| 在建工程 | 151,828,694.62 | 147,740,093.99 | 534,588,012.63 | 531,754,209.23 |
| 使用权资产 | 326,966.04 | 574,484.91 | 1,040,447.72 | 1,506,410.54 |
| 无形资产 | 143,731,427.14 | 149,322,190.61 | 174,684,686.93 | 180,069,466.04 |
| 长期待摊费用 | 1,883,902.08 | 2,034,364.98 | 3,739,930.4 | 4,007,056.31 |
| 其他非流动资产 | 27,512,658.44 | 14,892,431.98 | 14,644,811.87 | 15,217,205.37 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 593,674,627.65 | 589,520,367.36 | 986,182,222.26 | 993,674,051.8 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,723,742,799.34 | 1,812,138,179.73 | 2,005,628,037.66 | 2,057,173,323.26 |
| 流动负债: | | | | |
| 短期借款 | 240,574,100.34 | 283,967,406.71 | 294,235,203.95 | 268,915,116.01 |
| 应付票据及应付账款 | 17,034,395.2 | 6,776,034.24 | 24,001,600.54 | 26,734,487.68 |
| 其中：应付票据 | 3,699,264.08 | - | - | - |
| 应付账款 | 13,335,131.12 | 6,776,034.24 | 24,001,600.54 | 26,734,487.68 |
| 合同负债 | 1,841,351.53 | 2,676,810.67 | 1,064,228.78 | 1,516,488.48 |
| 应付职工薪酬 | 12,576,136.3 | 18,112,460.65 | 19,605,456.37 | 16,247,787.49 |
| 应交税费 | 801,351.95 | 808,358.56 | 1,345,296.63 | 912,388.93 |
| 其他应付款合计 | 19,889,636.1 | 23,156,351.64 | 31,608,952.72 | 24,100,636.37 |
| 其中:应付利息 | - | - | 397,028.1 | 363,992.23 |
| 一年内到期的非流动负债 | 122,543,301.52 | 59,585,223.25 | 104,221,349.83 | 134,814,883.79 |
| 其他流动负债 | 24,220.29 | 121,924.22 | 140,494.71 | 213,516.66 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 415,284,493.23 | 395,204,569.94 | 476,222,583.53 | 473,455,305.41 |
| 非流动负债: | | | | |
| 长期借款 | 17,936,000 | 79,362,291.68 | 50,178,000 | 52,420,000 |
| 长期应付款 | 125,630,300 | 125,630,300 | 232,548,663.41 | 232,357,511.24 |
| 递延收益 | 67,680,567.16 | 70,629,621.21 | 97,464,375.26 | 116,713,429.31 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 211,246,867.16 | 275,622,212.89 | 380,191,038.67 | 401,490,940.55 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 626,531,360.39 | 670,826,782.83 | 856,413,622.2 | 874,946,245.96 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 374,578,653 | 374,578,653 | 374,578,653 | 374,578,653 |
| 资本公积 | 2,723,191,887.05 | 2,723,191,887.05 | 2,723,191,887.05 | 2,723,191,887.05 |
| 其他综合收益 | 44,318.39 | 22,758.93 | 921.27 | 14,907.09 |
| 未分配利润 | -2,000,603,419.49 | -1,956,481,902.08 | -1,948,557,045.86 | -1,915,558,369.84 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,097,211,438.95 | 1,141,311,396.9 | 1,149,214,415.46 | 1,182,227,077.3 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,097,211,438.95 | 1,141,311,396.9 | 1,149,214,415.46 | 1,182,227,077.3 |
| 负债和股东权益合计 | 1,723,742,799.34 | 1,812,138,179.73 | 2,005,628,037.66 | 2,057,173,323.26 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |